Developer docs
API playgroundTry for free, no card

Search company profiles

Aurum Biosciences

Full company profile

uuid00039xm

Namestring
Aurum Biosciences
Legal namestring
Aurum Biosciences Ltd
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Aurum Biosciences is a UK clinical-stage biopharmaceutical company founded in 2015 as a spinout from NHS Greater Glasgow and Clyde, InnoScot Health, and the University of Glasgow. Headquartered at the Imaging Centre of Excellence at Glasgow's Queen Elizabeth University Hospital, the company is developing ABL-101, an injectable perfluorocarbon-based oxygen carrier approximately 45 times smaller than a red blood cell. ABL-101 is designed to bypass vascular blockages and deliver oxygen directly to ischemic tissue, addressing what the company estimates is a treatment gap affecting 90% of acute ischemic stroke patients globally who currently receive no direct therapy. The intended end users are acute stroke patients, with follow-on indications explored in spinal cord injury, cardiac arrest, traumatic brain injury, and heart attack.

The platform is differentiated by its theranostic capability, acting simultaneously as therapy and diagnostic. ABL-101 pairs with the proprietary Glasgow Oxygen Level Dependent (GOLD) MRI technique to identify salvageable brain tissue (penumbra) through direct metabolic imaging, and can also be visualised via fluorine-19 (19F) MRI as an inflammation contrast agent following macrophage uptake. Five granted patent families protect the platform, with IP coverage extending into the 2040s. The company has completed Phase 1 and Phase 2a studies in 43 patients with a reported good safety profile, and is preparing two Phase 2 trials for 2026/2027 — an acute stroke trial in India and a carotid arteriosclerosis imaging trial in Switzerland under SwissMedic approval.

Aurum is pre-revenue and operates a licensing-and-partnership business model. Future revenue is intended to derive from product sales and licensing royalties, with a £10m Series A currently being raised to fund Phase 2 development, manufacturing scale-up in India, and out-licensing agreements. Backers include Wellcome Trust, Scottish Enterprise, InnoScot Health, Tricapital Angels, and Infinion Biopharma; strategic partners include Tenax Therapeutics (US development rights) and the University of Lausanne (imaging collaboration). Targeted near-term monetisation milestones are a 2028 inflammation imaging licensing deal and Indian market authorisation by 2031.

Short descriptiontext

Aurum Biosciences is a Glasgow-based clinical-stage biopharmaceutical company developing ABL-101, a perfluorocarbon-based injectable oxygen carrier functioning as a theranostic for acute ischemic stroke treatment and inflammation imaging. The company is pre-revenue and licensing-focused, targeting Phase 2 trials in 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGlasgow, United Kingdom
HQ citystring
Glasgow
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oxygen carrier therapy, acute stroke treatment, theranostic imaging agents, perfluorocarbon emulsion drug, biopharmaceutical drug development
Industry5 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical Laboratories621511
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Acute Stroke Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1ABL-101 Product Sales
TypeOne Time License
Description

Revenue from sales of ABL-101 as a therapeutic and diagnostic product for acute ischemic stroke and inflammation imaging once regulatory approvals are obtained. Target market authorisation in India by 2031, with global licensing discussions.

aurumbiosciences.com
2Inflammation Imaging Licensing
TypeLicensing Royalties
Description

Licensing revenue from the inflammation imaging technology as a standalone commercial product, with licensing target of 2028 ahead of full stroke market authorisation.

aurumbiosciences.com
3Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

Partnership deals with pharmaceutical companies for development and commercialisation rights in various territories, such as the Tenax Therapeutics agreement for US market development.

aurumbiosciences.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aurum Biosciences is developing ABL-101, an injectable perfluorocarbon-based oxygen carrier that is 45 times smaller than a red blood cell and functions as a theranostic, simultaneously delivering oxygen directly to dying tissue and enabling MRI-based metabolic imaging to identify salvageable brain tissue in acute ischemic stroke patients. The product is currently in Phase 2 clinical development, with two trials planned for 2026/2027 — an acute stroke trial in India and a carotid arteriosclerosis inflammation imaging trial in Switzerland — and is pursuing market authorisation in India by 2031.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Aurum Biosciences is a clinical-stage biopharmaceutical company developing ABL-101, a perfluorocarbon-based injectable oxygen carrier that is 45 times smaller than a red blood cell. ABL-101 functions as a theranostic (therapy + diagnostic), simultaneously delivering oxygen to oxygen-deprived tissue and enabling MRI-based metabolic imaging to identify salvageable tissue. The company's pipeline includes Phase 2 clinical trials for acute stroke (India) and carotid arteriosclerosis inflammation imaging (Switzerland). Follow-on indications being developed include heart disease, cardiac arrest, traumatic brain injury, spinal cord injury, and oncology.

Product and service1 record
1ABL-101
CategoryAcute Stroke Therapeutics / Theranostic Imaging
Description

ABL-101 is an injectable perfluorocarbon-based oxygen carrier that is 45 times smaller than a red blood cell, functioning as a theranostic (combined therapy + diagnostic). It bypasses blockages and collateral vessels to deliver oxygen directly to dying tissue in acute ischemic stroke, while simultaneously enabling MRI-based metabolic imaging via the proprietary Glasgow Oxygen Level Dependent (GOLD) technique to identify salvageable brain tissue and fluorine-19 MRI for inflammation imaging in atherosclerotic plaques.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-11-22
Description

MRI research collaboration with Dr Ruud van Heeswijk's group testing ABL-101 as 19F inflammation imaging contrast agent. Currently running Phase 2 carotid arteriosclerosis imaging trial approved by SwissMedic.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2015-11-13
Description

US specialty pharmaceutical company (NASDAQ: TENX) based in North Carolina. Agreement gives Aurum full rights to develop Oxycyte in stroke. Originally licensed Oxycyte product for TBI with stroke indication development rights. Strategic R&D and commercial partnership for US market.

Strategic tierCoreTypeTechnology or Integration
Description

Long-term research collaboration developing the GOLD MRI technique. GEMRIC pre-clinical 7T scanner facility. Co-developed Glasgow Oxygen Level Dependent imaging technology. Source of original technology spinout.

Strategic tierCoreTypeTechnology or Integration
Description

Original spinout partner in 2015 along with InnoScot Health and University of Glasgow. Clinical trial site at Queen Elizabeth University Hospital. Source of clinical expertise and original technology development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
1HbO2 Therapeutics
TypeDirect peer
Description

HbO2 Therapeutics is developing Hemopure (bovine HBOC) for anaemia and ischaemic indications. Direct peer in the blood substitute/oxygen carrier therapeutic class with comparable mechanism (oxygen delivery to hypoxic tissue).

TypeEmerging player
Description

NoNO Inc. is a clinical-stage biotech developing therapeutics for acute ischaemic stroke and traumatic brain injury. Emerging peer in the same clinical indication space (acute stroke neuroprotection) with comparable stage and target patient population.

TypeDirect peer
Description

Prolong Pharmaceuticals is developing Sanguinate, a hemoglobin-based oxygen carrier for sickle cell disease and ischaemic conditions. Comparable as a therapeutic oxygen carrier targeting tissue oxygen deprivation, though using a different mechanism.

TypeBroad incumbent
Description

Penumbra is a larger, established medical device company with a leading stroke thrombectomy portfolio. Adjacent incumbent operating in the same acute stroke intervention space that ABL-101 ultimately aims to expand treatment access within.

TypeBroad incumbent
Description

Tenax Therapeutics is a US specialty pharmaceutical company (NASDAQ: TENX) and Aurum's existing US development partner for stroke. Comparable as a small-cap clinical-stage pharma focused on critical care / cardiovascular indications.

TypeDirect peer
Description

NuvOx Pharma is developing NanO2, an injectable perfluorocarbon-based oxygen carrier for stroke, heart attack, and cancer indications. Direct peer to Aurum given shared PFC oxygen-carrier mechanism and overlapping clinical indications.

TypeBroad incumbent
Description

Lantheus Holdings is an established radiopharmaceutical/diagnostic imaging company. Relevant peer given the imaging/contrast-agent dimension of ABL-101's theranostic platform and comparable commercial diagnostic imaging business model.

TypeBroad incumbent
Description

Bracco Imaging is a global diagnostic imaging contrast agent company. Relevant peer given ABL-101's theranostic contrast/diagnostic imaging application using 19F MRI and GOLD technique.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aurum Biosciences

Acute Stroke Therapeuticsaurumbiosciences.com

Aurum Biosciences is a Glasgow-based clinical-stage biopharmaceutical company developing ABL-101, a perfluorocarbon-based injectable oxygen carrier functioning as a theranostic for acute ischemic stroke treatment and inflammation imaging. The company is pre-revenue and licensing-focused, targeting Phase 2 trials in 2026.

What Aurum Biosciences does

Aurum Biosciences is a UK clinical-stage biopharmaceutical company founded in 2015 as a spinout from NHS Greater Glasgow and Clyde, InnoScot Health, and the University of Glasgow. Headquartered at the Imaging Centre of Excellence at Glasgow's Queen Elizabeth University Hospital, the company is developing ABL-101, an injectable perfluorocarbon-based oxygen carrier approximately 45 times smaller than a red blood cell. ABL-101 is designed to bypass vascular blockages and deliver oxygen directly to ischemic tissue, addressing what the company estimates is a treatment gap affecting 90% of acute ischemic stroke patients globally who currently receive no direct therapy. The intended end users are acute stroke patients, with follow-on indications explored in spinal cord injury, cardiac arrest, traumatic brain injury, and heart attack.

The platform is differentiated by its theranostic capability, acting simultaneously as therapy and diagnostic. ABL-101 pairs with the proprietary Glasgow Oxygen Level Dependent (GOLD) MRI technique to identify salvageable brain tissue (penumbra) through direct metabolic imaging, and can also be visualised via fluorine-19 (19F) MRI as an inflammation contrast agent following macrophage uptake. Five granted patent families protect the platform, with IP coverage extending into the 2040s. The company has completed Phase 1 and Phase 2a studies in 43 patients with a reported good safety profile, and is preparing two Phase 2 trials for 2026/2027 — an acute stroke trial in India and a carotid arteriosclerosis imaging trial in Switzerland under SwissMedic approval.

Aurum is pre-revenue and operates a licensing-and-partnership business model. Future revenue is intended to derive from product sales and licensing royalties, with a £10m Series A currently being raised to fund Phase 2 development, manufacturing scale-up in India, and out-licensing agreements. Backers include Wellcome Trust, Scottish Enterprise, InnoScot Health, Tricapital Angels, and Infinion Biopharma; strategic partners include Tenax Therapeutics (US development rights) and the University of Lausanne (imaging collaboration). Targeted near-term monetisation milestones are a 2028 inflammation imaging licensing deal and Indian market authorisation by 2031.

Aurum Biosciences firmographics

Firmographics
Name
Aurum Biosciences
Legal name
Aurum Biosciences Ltd
Website
https://aurumbiosciences.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Aurum Biosciences is a Glasgow-based clinical-stage biopharmaceutical company developing ABL-101, a perfluorocarbon-based injectable oxygen carrier functioning as a theranostic for acute ischemic stroke treatment and inflammation imaging. The company is pre-revenue and licensing-focused, targeting Phase 2 trials in 2026.
Ownership category
akta.pro rank

Aurum Biosciences industry classification

Industry
Product category
Acute Stroke Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)
SIC
Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Oxygen carrier therapy
  • Acute stroke treatment
  • Theranostic imaging agents
  • Perfluorocarbon emulsion drug
  • Biopharmaceutical drug development

Where Aurum Biosciences is headquartered

Location

Headquarters

HQ city
Glasgow
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Aurum Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. ABL-101 Product Sales: Revenue from sales of ABL-101 as a therapeutic and diagnostic product for acute ischemic stroke and inflammation imaging once regulatory approvals are obtained. Target market authorisation in India by 2031, with global licensing discussions.
  2. Inflammation Imaging Licensing: Licensing revenue from the inflammation imaging technology as a standalone commercial product, with licensing target of 2028 ahead of full stroke market authorisation.
  3. Strategic Partnerships and Licensing: Partnership deals with pharmaceutical companies for development and commercialisation rights in various territories, such as the Tenax Therapeutics agreement for US market development.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Aurum Biosciences product offering

Product offering

Core offering

Aurum Biosciences is developing ABL-101, an injectable perfluorocarbon-based oxygen carrier that is 45 times smaller than a red blood cell and functions as a theranostic, simultaneously delivering oxygen directly to dying tissue and enabling MRI-based metabolic imaging to identify salvageable brain tissue in acute ischemic stroke patients. The product is currently in Phase 2 clinical development, with two trials planned for 2026/2027 — an acute stroke trial in India and a carotid arteriosclerosis inflammation imaging trial in Switzerland — and is pursuing market authorisation in India by 2031.

Product overview

Aurum Biosciences is a clinical-stage biopharmaceutical company developing ABL-101, a perfluorocarbon-based injectable oxygen carrier that is 45 times smaller than a red blood cell. ABL-101 functions as a theranostic (therapy + diagnostic), simultaneously delivering oxygen to oxygen-deprived tissue and enabling MRI-based metabolic imaging to identify salvageable tissue. The company's pipeline includes Phase 2 clinical trials for acute stroke (India) and carotid arteriosclerosis inflammation imaging (Switzerland). Follow-on indications being developed include heart disease, cardiac arrest, traumatic brain injury, spinal cord injury, and oncology.

Differentiator

Problem solved

Functional benefit

Products and services

  • ABL-101 ABL-101 is an injectable perfluorocarbon-based oxygen carrier that is 45 times smaller than a red blood cell, functioning as a theranostic (combined therapy + diagnostic). It bypasses blockages and collateral vessels to deliver oxygen directly to dying tissue in acute ischemic stroke, while simultaneously enabling MRI-based metabolic imaging via the proprietary Glasgow Oxygen Level Dependent (GOLD) technique to identify salvageable brain tissue and fluorine-19 MRI for inflammation imaging in atherosclerotic plaques.

Companies that use Aurum Biosciences

Customer profile

Segments3 records

Ideal customer profiles3 records

Aurum Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aurum Biosciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and core.

  • University of Lausanne / Dr Ruud van HeeswijkmajorStrategic or Co-development Partner · 22 November 2019MRI research collaboration with Dr Ruud van Heeswijk's group testing ABL-101 as 19F inflammation imaging contrast agent. Currently running Phase 2 carotid arteriosclerosis imaging trial approved by SwissMedic.
  • Tenax TherapeuticsmajorStrategic or Co-development Partner · 13 November 2015US specialty pharmaceutical company (NASDAQ: TENX) based in North Carolina. Agreement gives Aurum full rights to develop Oxycyte in stroke. Originally licensed Oxycyte product for TBI with stroke indication development rights. Strategic R&D and commercial partnership for US market.
  • University of GlasgowcoreTechnology or IntegrationLong-term research collaboration developing the GOLD MRI technique. GEMRIC pre-clinical 7T scanner facility. Co-developed Glasgow Oxygen Level Dependent imaging technology. Source of original technology spinout.
  • NHS Greater Glasgow and ClydecoreTechnology or IntegrationOriginal spinout partner in 2015 along with InnoScot Health and University of Glasgow. Clinical trial site at Queen Elizabeth University Hospital. Source of clinical expertise and original technology development.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Aurum Biosciences competitors and assessment

Company assessment

Direct peers

  • HbO2 Therapeutics: HbO2 Therapeutics is developing Hemopure (bovine HBOC) for anaemia and ischaemic indications. Direct peer in the blood substitute/oxygen carrier therapeutic class with comparable mechanism (oxygen delivery to hypoxic tissue).
  • Prolong Pharmaceuticals: Prolong Pharmaceuticals is developing Sanguinate, a hemoglobin-based oxygen carrier for sickle cell disease and ischaemic conditions. Comparable as a therapeutic oxygen carrier targeting tissue oxygen deprivation, though using a different mechanism.
  • NuvOx Pharma: NuvOx Pharma is developing NanO2, an injectable perfluorocarbon-based oxygen carrier for stroke, heart attack, and cancer indications. Direct peer to Aurum given shared PFC oxygen-carrier mechanism and overlapping clinical indications.

Emerging players

  • NoNO Inc. NoNO Inc. is a clinical-stage biotech developing therapeutics for acute ischaemic stroke and traumatic brain injury. Emerging peer in the same clinical indication space (acute stroke neuroprotection) with comparable stage and target patient population.

Broad incumbents

  • Penumbra: Penumbra is a larger, established medical device company with a leading stroke thrombectomy portfolio. Adjacent incumbent operating in the same acute stroke intervention space that ABL-101 ultimately aims to expand treatment access within.
  • Tenax Therapeutics: Tenax Therapeutics is a US specialty pharmaceutical company (NASDAQ: TENX) and Aurum's existing US development partner for stroke. Comparable as a small-cap clinical-stage pharma focused on critical care / cardiovascular indications.
  • Lantheus Holdings: Lantheus Holdings is an established radiopharmaceutical/diagnostic imaging company. Relevant peer given the imaging/contrast-agent dimension of ABL-101's theranostic platform and comparable commercial diagnostic imaging business model.
  • Bracco Imaging: Bracco Imaging is a global diagnostic imaging contrast agent company. Relevant peer given ABL-101's theranostic contrast/diagnostic imaging application using 19F MRI and GOLD technique.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Aurum Biosciences social profiles

Digital presence

Aurum Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aurum Biosciences leadership team

Management profile

Number of profiles

Profiles6 records

Aurum Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aurum Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurum Biosciences

What does Aurum Biosciences do?

Aurum Biosciences is developing ABL-101, an injectable perfluorocarbon-based oxygen carrier that is 45 times smaller than a red blood cell and functions as a theranostic, simultaneously delivering oxygen directly to dying tissue and enabling MRI-based metabolic imaging to identify salvageable brain tissue in acute ischemic stroke patients. The product is currently in Phase 2 clinical development, with two trials planned for 2026/2027 — an acute stroke trial in India and a carotid arteriosclerosis inflammation imaging trial in Switzerland — and is pursuing market authorisation in India by 2031.

Is Aurum Biosciences a public or private company?

Aurum Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aurum Biosciences founded?

Aurum Biosciences was founded in 2015. It employs 1 to 10 people.

Where is Aurum Biosciences based?

Aurum Biosciences is headquartered in Glasgow, United Kingdom, in the Europe region.

How does Aurum Biosciences make money?

Three revenue lines are on record. ABL-101 Product Sales are the primary driver. The others are inflammation Imaging Licensing and strategic Partnerships and Licensing.

Who are Aurum Biosciences's main competitors?

Direct peers on record are HbO2 Therapeutics, Prolong Pharmaceuticals and NuvOx Pharma. NoNO Inc. is listed as an emerging player. Broad incumbents are Penumbra, Tenax Therapeutics, Lantheus Holdings and Bracco Imaging.

Does Aurum Biosciences have an API?

No public API is recorded for Aurum Biosciences.

What industry is Aurum Biosciences in?

Aurum Biosciences's product category is Acute Stroke Therapeutics. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DIGITScots Biopharma Firm Gets New Funding for Innovative TechScottish biopharmaceutical firm Aurum Biosciences has raised nearly £730,000 in the first tranche of a new funding round to develop its ABL-101 therapeutic and diagnostic technology. The investment is supported by existing and new investors including InnoScot Health, Scottish Enterprise, and co-founder Dr Celestine Santosh. This capital will advance the platform ahead of further planned growth and clinical trials for conditions such as stroke and spinal cord injury.AurumbiosciencesScottish biopharma company’s state-of-the-art technology attracts £730k in fresh investment – Aurum BiosciencesScottish biopharmaceutical company Aurum Biosciences has raised nearly £730,000 in the first tranche of a new equity funding round to develop its ABL-101 therapeutic and diagnostic technology. The investment, supported by investors including InnoScot Health, Scottish Enterprise, and TRICAPITAL, will advance the platform's development for treating conditions such as acute stroke and spinal cord injury.openPR.comArtificial Blood Market Outlook 2023: Industry Share, Growth, Drivers, Emerging Technologies, and Forecast Research Report 2030 | Aurum Biosciences (U.K.), HEMARINA (France)The global artificial blood market is expected to grow significantly, driven by increasing demand for blood transfusions and limited donated blood supply. Perfluorocarbon-based oxygen carriers are expected to dominate, while hemoglobin-based carriers are gaining popularity. The market is segmented by type, application, and geography, with key players including Aurum Biosciences and HEMARINA.BioSpacePressure BioSciences Receives $1.5M Contract for UltraShear Nanoemulsified CBDPressure BioSciences and CBD Supply MD signed a manufacturing and distribution agreement for UltraShear nanoemulsified CBD topical spray. The deal is expected to generate over $1.5 million in revenue for PBIO in 2023, with Phase I shipment of 850 vials by mid-April 2023.BioSpacePressure BioSciences Awarded Second U.S. Patent for Its Revolutionary Ultra Shear Technology Platform, for Its Innovative NanoGap ValvePressure BioSciences announced its second U.S. patent for its Ultra Shear Technology platform, covering a compact valve with throttling capability. The patent brings the company's UST IP estate to seven U.S. and 30 worldwide patents. The company expects the technology to drive strong sales growth and profitability in 2022.openPR.comArtificial Blood Substitutes Market 2020 Estimated To Expand at a Robust CAGR by 2025 | International Key Players - Hemoglobin Oxygen Therapeutics, Aurum Biosciences, HemarinaBusiness Industry Reports released a market research study on the Global Artificial Blood Substitutes Market, forecasting robust expansion through 2025 driven by demand for alternatives to human blood. The report highlights key industry players including Hemoglobin Oxygen Therapeutics, Aurum Biosciences, and Hemarina, while noting that North America is expected to lead in growth due to the presence of major ecosystem participants.